Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 1/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.45 |
| ▸ | ATM | Q13315 | 1/20 | 0.45 |
| ▸ | CACNA1G | O43497 | 2/20 | 0.43 |
| ▸ | NPY2R | P49146 | 1/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Acetaldehyde SCHEMBL1504926 | 0.96 | MEN1 (0.42) | MEN1KMT2AATMCACNA1GNPY2R | |
| SCHEMBL10277096 | 0.77 | MEN1 (0.50) | MEN1KMT2AATMCACNA1GNPY2R | |
| SCHEMBL1504924 | 0.76 | NPY2R (0.45) | MEN1KMT2AATMCACNA1GNPY2R | |
| SCHEMBL995911 | 0.74 | NPY2R (0.48) | MEN1KMT2AATMCACNA1GNPY2R | |
| SCHEMBL995912 | 0.74 | NPY2R (0.48) | MEN1KMT2AATMCACNA1GNPY2R | |
| SCHEMBL2902092 | 0.73 | KDM1A (0.55) | — | |
| Hydrochloric Acid SCHEMBL27870550 | 0.73 | MEN1 (0.50) | MEN1KMT2AATMPOLBRAB9A | |
| Hydrochloric Acid SCHEMBL27977672 | 0.73 | MEN1 (0.50) | MEN1KMT2AATMPOLBRAB9A | |
| SCHEMBL10277098 | 0.72 | NPY2R (0.42) | MEN1KMT2AATMNPY2R | |
| SCHEMBL25327624 | 0.71 | FAAH (0.43) | MEN1KMT2APOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2477968-B1 | N-[2-HYDROXYCARBAMOYL-2-(PIPERAZINYL)ETHYL]BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS | GALDERMA RES & DEV (FR) | 2013-10-23 | — | — | EP | disclosed |
| US-20120178934-A1 | N- [2-HYDROXYCARBAMOYL-2- (PIPERAZINYL) ETHYL] BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS | GALDERMA RESEARCH & DEVELOPMENT (FR) | 2012-07-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120178934-A1 | N- [2-HYDROXYCARBAMOYL-2- (PIPERAZINYL) ETHYL] BENZAMIDE COMPOUNDS, THEIR PREPARATION AND THEIR USE AS TACE INHIBITORS | CTSB, TPSAB1, PIGS | MEN1 3381/4885KMT2A 1626/4885ATM 2399/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.